Tonix Pharmaceut Stock Price, News & Analysis

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has announced a sponsored research agreement with the University of Maryland, Baltimore, to investigate the prevention of heart xenograft rejection using TNX-1500, a monoclonal antibody targeting CD40-ligand. Preclinical studies will use genetically-modified porcine hearts from Revivicor, Inc. A positive outcome could support an IND application and further human clinical trials. TNX-1500, designed to reduce thrombosis risk, may play a crucial role in preventing organ rejection. A Phase 1 study is anticipated to initiate in Q2 2023.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced preliminary results from a recent presentation on migraine treatments at the HCOP Winter Conference. The data indicate that magnesium enhances oxytocin’s analgesic effects and that intranasal oxytocin is effectively delivered to the trigeminal ganglia in humans, a key area related to migraines. Additionally, it was discovered that oxytocin receptors co-express with CGRP in human trigeminal neurons. Notably, sex differences were identified in oxytocin potency, with findings suggesting that females may respond better to oxytocin treatments. Tonix received FDA clearance for a Phase 2 study of TNX-1900, set to start enrollment in Q1 2023.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced it regained compliance with Nasdaq’s minimum bid price requirement, closing at or above $1.00 per share for 10 consecutive days. This compliance ensures continued listing on The Nasdaq Capital Market. Tonix is a clinical-stage biopharmaceutical company focused on developing therapeutics across various areas, including CNS, rare diseases, immunology, and infectious diseases. Key candidates include TNX-102 SL for fibromyalgia and Long COVID, TNX-1300 for cocaine intoxication, and TNX-801 for smallpox and monkeypox. Interim data for various studies is expected throughout 2023.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced an oral presentation by Dr. Tom Hobman at the 2nd Wnt & β-catenin Targeted Drug Development Conference on January 26, 2023. The presentation, titled “Targeting the Wnt/β-catenin pathway as a broad-spectrum antiviral strategy,” highlighted research on Wnt/β-catenin signaling pathway inhibitors as potential broad-spectrum antivirals against SARS-CoV-2. The CEO emphasized the need for such therapeutics to combat future pandemics. Tonix's lead candidate, TNX-102 SL, is in mid-Phase 3 for fibromyalgia, with interim data expected in mid-2023, further underlining their commitment to developing innovative therapies.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced the publication of a research paper detailing the development of rapid imaging assays for therapeutic antibodies against the monkeypox virus. This research was conducted at their Infectious Disease R&D Center in Frederick, Maryland. The study demonstrated the efficacy of the TNX-3400 platform in identifying antibodies that can neutralize the vaccinia virus, which is akin to monkeypox. The company aims to leverage this technology for combination therapies targeting monkeypox and smallpox. The TNX-3400 platform serves as a foundation for potential broad-spectrum antiviral treatments.

Tonix Pharmaceuticals has appointed Dr. Zeil Rosenberg as Executive Vice President, Medical, to lead clinical development for its vaccine and antiviral programs. Dr. Rosenberg will oversee key candidates like TNX-801 for smallpox and monkeypox, TNX-1850 for COVID-19, and monoclonal antibodies TNX-3600 and TNX-3800 targeting severe COVID-19 in immunocompromised patients. His extensive experience in infectious disease and successful vaccine trials from his previous positions at PPD and BD is expected to strengthen Tonix's clinical development efforts during a critical time for its product pipeline.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will present at Biotech Showcase 2023 from January 9-11, 2023, at Hilton San Francisco Union Square. The presentation is scheduled for January 10 at 3:00 p.m. PT. A live webcast will be available on the company’s website. Tonix focuses on developing therapeutics for various diseases, with lead candidate TNX-102 SL in mid-Phase 3 for fibromyalgia. Other programs target Long COVID, cocaine intoxication, chronic migraine, major depressive disorder, and infectious diseases.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has randomized 50% of participants in the Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia. An interim analysis by an Independent Data Monitoring Committee (IDMC) is anticipated in Q2 2023, with topline results expected in Q4 2023. Positive outcomes in RESILIENT, combined with past positive results from the RELIEF study, could support an NDA submission. Fibromyalgia affects 6-12 million adults in the U.S., highlighting the need for new non-opioid treatments, as current options have not satisfied patient needs since 2009.

Tonix Pharmaceuticals (Nasdaq: TNXP) has secured an exclusive license from Curia Global, Inc. for the development of three humanized murine monoclonal antibodies aimed at treating or preventing SARS-CoV-2 infections. This move comes as existing monoclonal antibody therapies struggle with new COVID-19 variants. CEO Seth Lederman emphasized the need for next-generation treatments, especially for immunocompromised individuals at higher risk of severe outcomes. Tonix aims to leverage its capabilities to expand its COVID-19 therapeutic pipeline.